Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(25%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_4
1
13%
Ph phase_2
3
38%
Ph phase_1
1
13%
Ph phase_3
1
13%
Ph not_applicable
2
25%

Phase Distribution

1

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
1(12.5%)
Phase 4Post-market surveillance
1(12.5%)
N/ANon-phased studies
2(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(5)
Completed(3)

Detailed Status

Not yet recruiting3
Completed3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (12.5%)
Phase 23 (37.5%)
Phase 31 (12.5%)
Phase 41 (12.5%)
N/A2 (25.0%)

Trials by Status

recruiting225%
not_yet_recruiting338%
completed338%

Recent Activity

Clinical Trials (8)

Drug Details

Intervention Type
OTHER
Total Trials
8